Laurus Labs Croissance future
Future contrôle des critères 3/6
Laurus Labs devrait augmenter ses bénéfices et son chiffre d'affaires de 19.1% et de 13.3% par an respectivement. Le BPA devrait croître de de 18.4% par an. Le rendement des capitaux propres devrait être 18.7% dans 3 ans.
Informations clés
19.1%
Taux de croissance des bénéfices
18.39%
Taux de croissance du BPA
| Pharmaceuticals croissance des bénéfices | 16.6% |
| Taux de croissance des recettes | 13.3% |
| Rendement futur des capitaux propres | 18.73% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 20 May 2026 |
Mises à jour récentes de la croissance future
Recent updates
Mise à jour du récit • Apr 30
LAURUSLABS: Upcoming Dividend Decision And Stable Assumptions Will Support Future Upside
Analysts have kept the Laurus Labs fair value estimate unchanged at ₹1,270, with small tweaks to revenue growth, profit margin and P/E assumptions. These reflect updated models rather than a shift in overall conviction.Mise à jour du récit • Apr 15
LAURUSLABS: Stronger Fundamentals And Upcoming Board Decisions Will Support Upside
Analysts have slightly reduced the Laurus Labs fair value estimate to ₹1,270 from ₹1,280 after updating assumptions on revenue growth, margins, and future P/E, while keeping the overall risk profile unchanged. Analyst Commentary Recent Street research on a different company, Laureate Education, still gives you a sense of how bullish analysts may think when they see improving fundamentals, supportive macro factors, or cleaner execution.
Mise à jour du récit • Apr 01
LAURUSLABS: Currency And Execution Uncertainties Will Likely Cap Margin Upside
Analysts have made a small upward tweak to the Laurus Labs fair value estimate, with the price target moving from ₹540.28 to ₹543.09. This reflects updated assumptions on revenue growth and profitability.Mise à jour du récit • Mar 18
LAURUSLABS: Higher Margin Assumptions Will Likely Struggle Against Execution Risks
Narrative Update on Laurus Labs The updated analyst price target for Laurus Labs moves from about ₹330 to roughly ₹540. Analysts point to revised assumptions for margins and future P/E, along with broadly steady growth expectations, as key drivers of the change.Mise à jour du récit • Mar 04
LAURUSLABS: Steady Fair Value And Solid Fundamentals Will Support Upside
Analysts have kept their price target for Laurus Labs steady at ₹1,280, reflecting small adjustments to assumptions on discount rate, revenue growth, profit margin and future P/E. These changes are consistent with recent Street research, where targets shifted within a relatively tight range and analysts cited solid fundamentals alongside mixed near term signals.
Mise à jour du récit • Feb 18
LAURUSLABS: Future Returns Will Rely On Confidence In Elevated P E Assumptions
Narrative Update: Laurus Labs Analyst Price Target Analysts have maintained their Laurus Labs price target at ₹913.47, citing largely unchanged assumptions around revenue, profit margins, discount rate, and forward P/E as the basis for keeping fair value steady. Analyst Commentary Analysts covering Laurus Labs are using a similar playbook to recent work on other education and healthcare names, where price targets are adjusted mainly on valuation inputs rather than big changes in growth assumptions.Mise à jour du récit • Feb 03
LAURUSLABS: Future Returns Will Depend On Confidence In Rich P E Assumptions
Analysts have lifted their fair value estimate for Laurus Labs from ₹863.13 to ₹913.47, citing slightly higher assumptions for revenue growth, profit margins and future P/E multiples, consistent with recent upward target revisions seen in related Street research. Analyst Commentary Bullish analysts point to the higher fair value estimate of ₹913.47 as support for a more constructive view on Laurus Labs, even though inputs are only slightly adjusted.Article d’analyse • Jan 28
Results: Laurus Labs Limited Beat Earnings Expectations And Analysts Now Have New Forecasts
Laurus Labs Limited ( NSE:LAURUSLABS ) just released its quarterly report and things are looking bullish. It was...Article d’analyse • Jan 25
Laurus Labs Limited's (NSE:LAURUSLABS) Popularity With Investors Is Under Threat From Overpricing
With a price-to-earnings (or "P/E") ratio of 65.1x Laurus Labs Limited ( NSE:LAURUSLABS ) may be sending very bearish...Mise à jour du récit • Jan 20
LAURUSLABS: Future Returns Will Depend On Rich P E Assumptions Holding
Analysts have lifted their price target for Laurus Labs to ₹863 from about ₹822, reflecting updated assumptions on fair value, profit margins, and future P/E multiples. Analyst Commentary Bullish Takeaways Bullish analysts view the higher price target as a sign that current assumptions on Laurus Labs' fair value leave room for upside if the company executes consistently on profitability.Mise à jour du récit • Jan 06
LAURUSLABS: Interim Dividend And Higher P E Multiple Will Support Upside
Analysts have raised their price target on Laurus Labs from ₹1,025 to ₹1,280, citing updated assumptions for revenue growth, profit margins, and a higher future P/E multiple. What's in the News The Board of Directors approved an interim dividend of ₹0.80 per equity share of face value ₹2 for the 2025-26 financial year at the meeting held on October 23, 2025 (company filing).Mise à jour du récit • Dec 21
LAURUSLABS: Interim Dividend May Not Offset Softer Margins Ahead
Analysts have moderately raised their price target on Laurus Labs from ₹303.09 to ₹330.21, citing a slightly higher justified valuation multiple that more than offsets their marginally softer assumptions on revenue growth and profit margins. What's in the News The Board approved an interim dividend of INR 0.80 per equity share (40 percent of the face value of INR 2) for FY 2025-26, signaling confidence in cash flows and shareholder returns (company filing).Mise à jour du récit • Dec 07
LAURUSLABS: Future Returns Will Likely Hinge On Managing Execution Risks
Analysts have modestly increased their price target for Laurus Labs while maintaining fair value at ₹821.93, citing expectations of sustained earnings growth supported by a solid balance sheet, margin expansion, and revenue momentum from new market opportunities. Analyst Commentary Street research on comparable growth stories in the education and healthcare sectors highlights themes that are directly relevant for Laurus Labs, particularly around how markets price in multi year earnings expansion, balance sheet strength, and scalability in new markets.Mise à jour du récit • Nov 23
LAURUSLABS: Future Revenue Upside May Be Limited By Execution Risks
Analysts have raised their price target for Laurus Labs slightly, from ₹815.86 to ₹821.93. They cite expectations of stronger revenue growth supported by a robust balance sheet and expanding opportunities in new markets.Mise à jour du récit • Nov 04
LAURUSLABS: Margin Pressures From Rising Input Costs Will Weigh On Earnings
Analysts have raised their fair value price target for Laurus Labs from ₹724.14 to ₹815.86. They cite increased profitability outlook and sustained margin growth as key drivers for the revision.Article d’analyse • Oct 30
Laurus Labs' (NSE:LAURUSLABS) Dividend Will Be ₹0.80
Laurus Labs Limited ( NSE:LAURUSLABS ) will pay a dividend of ₹0.80 on the 22nd of November. Even though the dividend...Mise à jour du récit • Oct 21
Analysts Cite Growth Momentum and Strong Balance Sheet in Raising Laurus Labs Valuation Estimates
Analysts have raised their fair value estimate for Laurus Labs from ₹694.85 to ₹724.14. They cite continued revenue growth momentum and a strong balance sheet as key drivers for this upward revision.Article d’analyse • Oct 19
With Laurus Labs Limited (NSE:LAURUSLABS) It Looks Like You'll Get What You Pay For
Laurus Labs Limited's ( NSE:LAURUSLABS ) price-to-sales (or "P/S") ratio of 8.2x may look like a poor investment...Article d’analyse • Aug 31
Laurus Labs (NSE:LAURUSLABS) Seems To Use Debt Quite Sensibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Article d’analyse • Jul 20
Revenues Tell The Story For Laurus Labs Limited (NSE:LAURUSLABS) As Its Stock Soars 28%
The Laurus Labs Limited ( NSE:LAURUSLABS ) share price has done very well over the last month, posting an excellent...Article d’analyse • Jun 11
Investors Shouldn't Be Too Comfortable With Laurus Labs' (NSE:LAURUSLABS) Earnings
Unsurprisingly, Laurus Labs Limited's ( NSE:LAURUSLABS ) stock price was strong on the back of its healthy earnings...
Nouveau récit • Jan 26
CDMO Expansion May Impact Near-Term Margins But Pave Way For Future Revenue Streams
Heavy investment in CDMO and microbial precision initiatives may lead to revenue delays and short-term margin compression due to underutilized assets.Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 3/31/2029 | 102,621 | 15,804 | 6,088 | 16,669 | 6 |
| 3/31/2028 | 90,215 | 13,716 | 3,695 | 15,860 | 14 |
| 3/31/2027 | 78,928 | 11,074 | 1,234 | 13,655 | 11 |
| 3/31/2026 | 68,129 | 8,888 | 5,536 | 16,235 | N/A |
| 12/31/2025 | 67,216 | 8,433 | N/A | N/A | N/A |
| 9/30/2025 | 63,584 | 6,840 | 7,696 | 16,375 | N/A |
| 6/30/2025 | 59,286 | 5,088 | N/A | N/A | N/A |
| 3/31/2025 | 55,540 | 3,583 | -393 | 6,017 | N/A |
| 12/31/2024 | 52,733 | 2,003 | N/A | N/A | N/A |
| 9/30/2024 | 50,532 | 1,311 | -3,277 | 2,489 | N/A |
| 6/30/2024 | 50,540 | 1,482 | N/A | N/A | N/A |
| 3/31/2024 | 50,408 | 1,606 | -126 | 6,657 | N/A |
| 12/31/2023 | 49,821 | 1,879 | N/A | N/A | N/A |
| 9/30/2023 | 53,320 | 3,678 | 2,870 | 12,248 | N/A |
| 6/30/2023 | 56,834 | 5,637 | N/A | N/A | N/A |
| 3/31/2023 | 60,406 | 7,901 | 37 | 9,939 | N/A |
| 12/31/2022 | 60,845 | 9,176 | N/A | N/A | N/A |
| 9/30/2022 | 55,684 | 8,683 | 13 | 8,393 | N/A |
| 6/30/2022 | 51,960 | 8,374 | N/A | N/A | N/A |
| 3/31/2022 | 49,356 | 8,275 | 343 | 9,111 | N/A |
| 12/31/2021 | 49,227 | 8,937 | N/A | N/A | N/A |
| 9/30/2021 | 51,823 | 10,128 | -1,705 | 7,112 | N/A |
| 6/30/2021 | 51,177 | 10,532 | N/A | N/A | N/A |
| 3/31/2021 | 48,135 | 9,836 | 442 | 7,330 | N/A |
| 12/31/2020 | 42,407 | 7,971 | N/A | N/A | N/A |
| 9/30/2020 | 36,819 | 5,977 | 1,548 | 5,427 | N/A |
| 6/30/2020 | 32,555 | 4,120 | N/A | N/A | N/A |
| 3/31/2020 | 28,317 | 2,553 | 1,252 | 3,474 | N/A |
| 12/31/2019 | 26,277 | 1,883 | N/A | N/A | N/A |
| 9/30/2019 | 24,276 | 1,326 | N/A | 3,538 | N/A |
| 6/30/2019 | 23,035 | 923 | N/A | N/A | N/A |
| 3/31/2019 | 22,919 | 938 | N/A | 2,977 | N/A |
| 12/31/2018 | 22,170 | 957 | N/A | N/A | N/A |
| 9/30/2018 | 21,665 | 1,127 | N/A | N/A | N/A |
| 6/30/2018 | 21,168 | 1,453 | N/A | N/A | N/A |
| 3/31/2018 | 20,562 | 1,676 | N/A | 3,425 | N/A |
| 12/31/2017 | 19,687 | 1,917 | N/A | N/A | N/A |
| 9/30/2017 | 19,954 | 2,019 | N/A | N/A | N/A |
| 6/30/2017 | 19,733 | 2,014 | N/A | N/A | N/A |
| 3/31/2017 | 19,046 | 1,881 | N/A | 3,320 | N/A |
| 3/31/2016 | 17,776 | 1,337 | N/A | 1,820 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de LAURUSLABS ( 19.1% par an) est supérieure au taux d'épargne ( 6.9% ).
Bénéfices vs marché: Les bénéfices de LAURUSLABS ( 19.1% par an) devraient croître plus rapidement que le marché Indian ( 16.3% par an).
Croissance élevée des bénéfices: Les bénéfices de LAURUSLABS devraient augmenter, mais pas de manière significative.
Chiffre d'affaires vs marché: Le chiffre d'affaires de LAURUSLABS ( 13.3% par an) devrait croître plus rapidement que le marché Indian ( 10.8% par an).
Croissance élevée des revenus: Le chiffre d'affaires de LAURUSLABS ( 13.3% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de LAURUSLABS devrait être faible dans 3 ans ( 18.7 %).
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/22 12:10 |
| Cours de l'action en fin de journée | 2026/05/22 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2026/03/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Laurus Labs Limited est couverte par 22 analystes. 14 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Ashwin Mehta | Ambit Capital |
| null null | Antique Stockbroking Ltd. |